The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Open accessAbstract
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Self-citationTeachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Self-citationAhmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Self-citationSampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationGlobal Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
Self-citationManaging Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Grossman, S. A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 578
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Self-citationRivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 245
The natural history of EGFR and EGFRvIII in glioblastoma patients
Heimberger, A. B., Suki, D., Yang, D., Shi, W., & Aldape, K. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-38 · Cited by 235
Palma, L., Di Lorenzo, N., & Guidetti, B. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.6.0854 · Cited by 206
Relationship of lymphocyte invasion and survival of brain tumor patients
Brooks, W. H., Markesbery, W. R., Gupta, G. D., & Roszman, T. L. (1978) · Annals of Neurology · doi:10.1002/ana.410040305 · Cited by 206
Chen, F., Teachey, D. T., Pequignot, E., Frey, N., Porter, D., Maude, S. L., Grupp, S. A., June, C. H., Melenhorst, J. J., & Lacey, S. F. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.03.005 · Cited by 195
Self-citation“MIATA”—Minimal Information about T Cell Assays
Janetzki, S., Britten, C. M., Kalos, M., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., Old, L. J., Romero, P., Hoos, A., & Davis, M. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.007 · Cited by 190
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
van den Bent, M. J., Gao, Y., Kerkhof, M., Kros, J. M., Gorlia, T., van Zwieten, K., Prince, J., van Duinen, S., Sillevis Smitt, P. A., Taphoorn, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov013 · Cited by 180
Laport, G. G., Levine, B. L., Stadtmauer, E. A., Schuster, S. J., Luger, S. M., Grupp, S., Bunin, N., Strobl, F. J., Cotte, J., Zheng, Z., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0095 · Cited by 179
Self-citationFitz, C. D. V., Giacomini, C. P., Vogel, H. S., Jensen, K. C., Florio, T., Merlo, A., Pollack, J. R., & Wong, A. J. (2012) · Oncogene · doi:10.1038/onc.2012.280 · Cited by 143
Epidermal growth factor receptor targeting and challenges in glioblastoma
Thorne, A. H., Zanca, C., & Furnari, F. B. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov319 · Cited by 119
Prognosis of patients with multifocal glioblastoma: a case-control study
Patil, C. G., Yi, A., Elramsisy, A., Hu, J. L., Mukherjee, D. R., Irvin, D. K., Yu, J. S., Bannykh, S., Black, K. L., & Nuño, M. (2012) · Journal of neurosurgery · doi:10.3171/2012.7.jns12147 · Cited by 113
Ohno, M., Ohkuri, T., Kosaka, A., Tanahashi, K., June, C. H., Natsume, A., & Okada, H. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-21 · Cited by 108
Self-citationRapoport, A. P., Stadtmauer, E. A., Aqui, N. A., Vogl, D. T., Chew, A., Fang, H., Janofsky, S., Yager, K., Veloso, E. A., Zheng, Z., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0418 · Cited by 90
Self-citationTykocinski, E. S., Grant, R. A., Kapoor, G. S., Krejza, J., Bohman, L., Gocke, T. A., Chawla, S., Halpern, C. H., Lopinto, J., Melhem, E. R., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos073 · Cited by 79
Self-citationEGF receptor variant III as a target antigen for tumor immunotherapy
Li, G., & Wong, A. J. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.977 · Cited by 74
Fitz, C. D. V., Jensen, K. C., Nitta, R. T., Shain, A. H., Giacomini, C. P., & Wong, A. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2656 · Cited by 61
Targeting multiple kinases in glioblastoma multiforme
Sathornsumetee, S., & Reardon, D. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802692603 · Cited by 49
Wang, W., Wang, X., Doddareddy, R., Fink, D., McIntosh, T. S., Davis, H. M., & Zhou, H. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9545-8 · Cited by 47
Adoptive immunotherapy: good habits instilled at youth have long-term benefits
Paulos, C. M., Suhoski, M. M., Plesa, G., Jiang, T., Basu, S., Golovina, T. N., Jiang, S., Aqui, N. A., Powell, D. J., Levine, B. L., et al. (2008) · Immunologic Research · doi:10.1007/s12026-008-8070-9 · Cited by 44
Self-citationAntiangiogenic Strategies for Treatment of Malignant Gliomas
Chi, A. S., Norden, A. D., & Wen, P. Y. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.010 · Cited by 32
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials
Reardon, D. A., & Okada, H. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1748-7 · Cited by 11
Self-citation
Cited by
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Self-citationDelivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Self-citationManagement of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Metadata
- Authors
- O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., Isaacs, R., Mohan, S., Plesa, G., Lacey, S. F., Navenot, J.-M., Zheng, Z., Levine, B. L., Okada, H., June, C. H., Brogdon, J. L., & Maus, M. V.
- Venue
- Science Translational Medicine
- Published
- 2017-07-19
- Volume
- 9
- Issue
- 399
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2738678436
- Cited by
- 1,803
- References
- 50
- FWCI
- 52.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.